White House moves to put NIH research grants under a presidential board

President Trump has ordered a plan for a White House board to approve National Institutes of Health grants, tightening control of a 48 billion dollar budget^1,8. The New York Times reported the move as the White House taking control of NIH grants, and attributed the effort to Office of Management and Budget director Russell Vought².

Trump instructed Vought to prepare a draft executive order³. Politico, which first reported the request, said the president asked his budget chief to draft an order bringing health research funding under his control, with NIH director Jay Bhattacharya and Harvard University among the parties named⁵. Vought criticised the agency during an Oval Office meeting on Friday⁶, and clashed with Bhattacharya there over the grants⁷. A separate account framed the exercise as a review of grants the budget office considers ideological⁶. The clash took place in the Oval Office rather than in a budget process, which is an unusual venue for a dispute over research grant criteria^6,7.

Why it matters to investors

The NIH is the largest public funder of biomedical research, and a White House board sitting between the agency and its grantees changes who decides what gets funded^1,2. That is upstream of the academic work that feeds early-stage biotechnology, and upstream of the university budgets that support it⁵.

The immediate signal is the size of the discretionary pool involved: 48 billion dollars now subject to an approval layer that did not previously exist⁸. The reported dispute between the budget office and the agency’s own director indicates the change is contested inside the administration rather than agreed^6,7. A board approving individual grants is also a procedural change with a timing cost, since every award would pass through a body that does not yet exist^1,8.

What to watch

The first question is whether the executive order is actually signed, and in what form. At this stage the reporting describes an instruction to draft rather than a completed instrument^3,5.

The second is how a board would operate in practice, and whether grant decisions slow while it is stood up¹. Bhattacharya’s position is the internal variable, given the Oval Office clash reported by two outlets^6,7, and the named involvement of Harvard suggests specific institutions rather than the whole portfolio may be the first target^2,5. The Department of Health and Human Services is the other party named in the reporting, and its role in any new approval chain has not been set out⁵.